Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022

Descripción del Articulo

Medulloblastomas are the most common malignant brain neoplasms in children. Immunohistochemical(IHC) markers can determine a molecular classification, using the markers GAB1, YAP1, β-catenin, P53, and Ki67. The classification of these neoplasms into molecular groups has proven to be clinically and t...

Descripción completa

Detalles Bibliográficos
Autores: Gallegos Mendoza, Milagros, Paz Carrillo, Edith, Casavilca Zambrano, Sandro, Villa Robles, María del Rosario, Barrionuevo-Cornejo, Carlos
Formato: artículo
Fecha de Publicación:2025
Institución:Universidad de San Martín de Porres
Repositorio:Horizonte médico
Lenguaje:español
OAI Identifier:oai:horizontemedico.usmp.edu.pe:article/3285
Enlace del recurso:https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/3285
Nivel de acceso:acceso abierto
Materia:Meduloblastoma
Inmunohistoquímica
Niño
Neoplasias
Medulloblastoma
Immunohistochemistry
Child
Neoplasms
id REVHM_5948350f249b541f6d0631eca812b415
oai_identifier_str oai:horizontemedico.usmp.edu.pe:article/3285
network_acronym_str REVHM
network_name_str Horizonte médico
repository_id_str
dc.title.none.fl_str_mv Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
Asociación entre el perfil inmunohistoquímico y el desenlace clínico en pacientes con meduloblastoma tratados en un hospital pediátrico peruano, periodo 2013–2022
title Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
spellingShingle Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
Gallegos Mendoza, Milagros
Meduloblastoma
Inmunohistoquímica
Niño
Neoplasias
Medulloblastoma
Immunohistochemistry
Child
Neoplasms
title_short Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
title_full Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
title_fullStr Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
title_full_unstemmed Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
title_sort Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022
dc.creator.none.fl_str_mv Gallegos Mendoza, Milagros
Paz Carrillo, Edith
Casavilca Zambrano, Sandro
Villa Robles, María del Rosario
Barrionuevo-Cornejo, Carlos
author Gallegos Mendoza, Milagros
author_facet Gallegos Mendoza, Milagros
Paz Carrillo, Edith
Casavilca Zambrano, Sandro
Villa Robles, María del Rosario
Barrionuevo-Cornejo, Carlos
author_role author
author2 Paz Carrillo, Edith
Casavilca Zambrano, Sandro
Villa Robles, María del Rosario
Barrionuevo-Cornejo, Carlos
author2_role author
author
author
author
dc.subject.none.fl_str_mv Meduloblastoma
Inmunohistoquímica
Niño
Neoplasias
Medulloblastoma
Immunohistochemistry
Child
Neoplasms
topic Meduloblastoma
Inmunohistoquímica
Niño
Neoplasias
Medulloblastoma
Immunohistochemistry
Child
Neoplasms
description Medulloblastomas are the most common malignant brain neoplasms in children. Immunohistochemical(IHC) markers can determine a molecular classification, using the markers GAB1, YAP1, β-catenin, P53, and Ki67. The classification of these neoplasms into molecular groups has proven to be clinically and therapeutically significant. The clinical outcomes of medulloblastoma include death, adverseeffects or conditions, and tumor recurrence. The objective of this research was to determine the individual association between the IHC markers used for molecular group classification and the clinical outcome in patients with medulloblastoma treated at the Instituto Nacional de Salud del Niño (INSN - National Institute of Child Health) during the period 2013–2022. The population consisted of 58 patients. The individual IHC expression of GAB1, YAP1, β-catenin, p53, and Ki67 in paraffin-embedded biopsies was compared with the clinical outcomes. Descriptive statistics and bivariate analysis were used to determine associations. The desmoplastic/nodular variant was the most commonly observed histological type of medulloblastoma, and there was a high frequency of IHC expression of YAP1 and an association between IHC expression of YAP1 and adverse effects. The clinicopathological characteristics of our cases were similar to those described in China. The finding may be useful as a prognostic marker of adverse effects in pediatric medulloblastoma.
publishDate 2025
dc.date.none.fl_str_mv 2025-09-11
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/3285
10.24265/horizmed.2025.v25n3.09
url https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/3285
identifier_str_mv 10.24265/horizmed.2025.v25n3.09
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/3285/2342
dc.rights.none.fl_str_mv Derechos de autor 1970 Horizonte Médico (Lima)
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 1970 Horizonte Médico (Lima)
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad de San Martín de Porres. Facultad de Medicina Humana
publisher.none.fl_str_mv Universidad de San Martín de Porres. Facultad de Medicina Humana
dc.source.none.fl_str_mv Horizonte Médico (Lima); Vol. 25 No. 3 (2025): Julio-setiembre; e3285
Horizonte Médico (Lima); Vol. 25 Núm. 3 (2025): Julio-setiembre; e3285
Horizonte Médico (Lima); v. 25 n. 3 (2025): Julio-setiembre; e3285
2227-3530
1727-558X
reponame:Horizonte médico
instname:Universidad de San Martín de Porres
instacron:USMP
instname_str Universidad de San Martín de Porres
instacron_str USMP
institution USMP
reponame_str Horizonte médico
collection Horizonte médico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1844720564069990400
spelling Association between the immunohistochemical profile and clinical outcome in patients with medulloblastoma treated at a Peruvian pediatric hospital, 2013-2022Asociación entre el perfil inmunohistoquímico y el desenlace clínico en pacientes con meduloblastoma tratados en un hospital pediátrico peruano, periodo 2013–2022Gallegos Mendoza, MilagrosPaz Carrillo, Edith Casavilca Zambrano, SandroVilla Robles, María del RosarioBarrionuevo-Cornejo, Carlos Meduloblastoma Inmunohistoquímica Niño NeoplasiasMedulloblastoma Immunohistochemistry Child NeoplasmsMedulloblastomas are the most common malignant brain neoplasms in children. Immunohistochemical(IHC) markers can determine a molecular classification, using the markers GAB1, YAP1, β-catenin, P53, and Ki67. The classification of these neoplasms into molecular groups has proven to be clinically and therapeutically significant. The clinical outcomes of medulloblastoma include death, adverseeffects or conditions, and tumor recurrence. The objective of this research was to determine the individual association between the IHC markers used for molecular group classification and the clinical outcome in patients with medulloblastoma treated at the Instituto Nacional de Salud del Niño (INSN - National Institute of Child Health) during the period 2013–2022. The population consisted of 58 patients. The individual IHC expression of GAB1, YAP1, β-catenin, p53, and Ki67 in paraffin-embedded biopsies was compared with the clinical outcomes. Descriptive statistics and bivariate analysis were used to determine associations. The desmoplastic/nodular variant was the most commonly observed histological type of medulloblastoma, and there was a high frequency of IHC expression of YAP1 and an association between IHC expression of YAP1 and adverse effects. The clinicopathological characteristics of our cases were similar to those described in China. The finding may be useful as a prognostic marker of adverse effects in pediatric medulloblastoma.Los meduloblastomas son las neoplasias cerebrales malignas más frecuentes en niños. Los marcadores de inmunohistoquímica (IHQ) pueden determinar una clasificación molecular mediante los marcadores GAB1, YAP1, β-catenina, P53 y Ki-67. La clasificación de estas neoplasias en grupos moleculares ha demostrado tener impacto clínico y terapéutico. Los desenlaces clínicos del meduloblastoma incluyen el fallecimiento, efectos o condiciones adversas y recidiva del tumor. El objetivo de esta investigación fue determinar la asociación individual entre los marcadores de IHQ usados para la determinación de grupos moleculares y el desenlace clínico en los pacientes con meduloblastoma atendidos en el Instituto Nacional de Salud del Niño (INSN), periodo 2013-2022. La población fue de 58 pacientes. Se comparó la expresión IHQ individual de GAB1, YAP1, β-catenina, P53 y Ki-67 en biopsias embebidas en parafina con el desenlace clínico. Se usó estadística descriptiva y un análisis bivariado para determinar asociaciones. El tipo histológico más frecuente fue el desmoplásico nodular y hubo alta frecuencia de expresión IHQ de YAP1 y asociación entre la expresión IHQ de YAP1 y efectos adversos. Las características clínico-patológicas de nuestros casos fueron semejantes a lo descrito en China. El hallazgo encontrado puede ser útil como marcador pronóstico de efectos adversos en meduloblastomas pediátricos.Universidad de San Martín de Porres. Facultad de Medicina Humana2025-09-11info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/328510.24265/horizmed.2025.v25n3.09Horizonte Médico (Lima); Vol. 25 No. 3 (2025): Julio-setiembre; e3285Horizonte Médico (Lima); Vol. 25 Núm. 3 (2025): Julio-setiembre; e3285Horizonte Médico (Lima); v. 25 n. 3 (2025): Julio-setiembre; e32852227-35301727-558Xreponame:Horizonte médicoinstname:Universidad de San Martín de Porresinstacron:USMPspahttps://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/3285/2342Derechos de autor 1970 Horizonte Médico (Lima)https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessoai:horizontemedico.usmp.edu.pe:article/32852025-09-12T21:01:55Z
score 13.919782
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).